MOXEZA Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Moxeza, and what generic alternatives are available?
Moxeza is a drug marketed by Harrow Eye and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
This drug has twenty-three patent family members in fifteen countries.
The generic ingredient in MOXEZA is moxifloxacin hydrochloride. There are eighteen drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the moxifloxacin hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Moxeza
A generic version of MOXEZA was approved as moxifloxacin hydrochloride by TEVA PHARMS USA on February 18th, 2014.
Summary for MOXEZA
| International Patents: | 23 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 111 |
| Clinical Trials: | 1 |
| Patent Applications: | 1,594 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for MOXEZA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for MOXEZA |
| What excipients (inactive ingredients) are in MOXEZA? | MOXEZA excipients list |
| DailyMed Link: | MOXEZA at DailyMed |
Recent Clinical Trials for MOXEZA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Usona Institute | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for MOXEZA
Paragraph IV (Patent) Challenges for MOXEZA
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| MOXEZA | Ophthalmic Solution | moxifloxacin hydrochloride | 0.5% | 022428 | 1 | 2012-02-29 |
US Patents and Regulatory Information for MOXEZA
MOXEZA is protected by two US patents.
Patents protecting MOXEZA
Pharmaceutical compositions containing a fluoroquinolone antibiotic drug
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Pharmaceutical compositions containing a fluoroquinolone antibiotic drug
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Harrow Eye | MOXEZA | moxifloxacin hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 022428-001 | Nov 19, 2010 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Harrow Eye | MOXEZA | moxifloxacin hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 022428-001 | Nov 19, 2010 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MOXEZA
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Harrow Eye | MOXEZA | moxifloxacin hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 022428-001 | Nov 19, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
| Harrow Eye | MOXEZA | moxifloxacin hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 022428-001 | Nov 19, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
| Harrow Eye | MOXEZA | moxifloxacin hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 022428-001 | Nov 19, 2010 | ⤷ Try a Trial | ⤷ Try a Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MOXEZA
See the table below for patents covering MOXEZA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| South Korea | 0156375 | ⤷ Try a Trial | |
| Netherlands | 300111 | ⤷ Try a Trial | |
| Hungary | 211472 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for MOXEZA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0350733 | SPC/GB03/034 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: MOXIFLOXACIN AND PHARMACEUTICALLY USABLE HYDRATES AND ACID ADDITION SALTS THEREOF AND THE ALKALI METAL, ALKALINE EARTH METAL, SILVER AND GUANIDINIUM SALTS OF THE UNDERLYING CARBOXYLIC ACIDS AND THE RACEMATES THEREOF; REGISTERED: DE 45263.00.00 19990621; UK PL 000 10/0291 20030313 |
| 0350733 | 11/2000 | Austria | ⤷ Try a Trial | PRODUCT NAME: MOXIFLOXACIN, DESSEN PHARMAZEUTISCH VERWENDBARE HYDRATE UND SAEUREADDITIONSSALZE, DESSEN ALKALI-ERDALKALI-SILBER- UND GUANIDINIUMSALZE, SOWIE DESSEN C1 - C4 ALKYL- ODER; NAT. REGISTRATION NO/DATE: 1-23494, 1-23495, 1-23496 20000215; FIRST REGISTRATION: DE 45263.00.00 19990621 |
| 0350733 | C300111 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: MOXIFLOXACINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER MOXIFLOXACINEHYDROCHLORIDE; NAT. REGISTRATION NO/DATE: RVG 28118 RVG 28119 20021017; FIRST REGISTRATION: DE 45263.00.00 19990621 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
